Search Within

Andrew D Seidman

Formats
  1. Journal Article (175)
  2. Meeting Abstract (123)
  3. Conference Paper (9)
  4. Correspondence (3)
  5. Review (3)
  6. Book Section (2)
  7. Research Letter (2)
  8. Editorial (1)
Groups
  1. Breast Medicine Service (318)
  2. Department of Medicine (318)
  3. Solid Tumor Oncology Division (318)
  4. Survivorship Research (158)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (116)
  6. Epidemiology and Biostatistics (84)

More Groups

People
  1. Clifford Hudis (116)
  2. Larry Norton (99)
  3. Teresa Gilewski (38)
  4. Monica Fornier (37)
  5. Gabriella D'Andrea-Carlino (36)
  6. Violante Currie (32)

More People

Years
  1. 2025 (3)
  2. 2024 (4)
  3. 2023 (10)
  4. 2022 (6)
  5. 2021 (9)
  6. 2020 (6)

More Years

Publications
  1. Journal of Clinical Oncology (83)
  2. Breast Cancer Research and Treatment (25)
  3. Cancer Research (23)
  4. Clinical Breast Cancer (19)
  5. Seminars in Oncology (16)
  6. Oncology (Norwalk) (14)

More Publications

Publishers
  1. American Society of Clinical Oncology (84)
  2. Elsevier Inc. (55)
  3. Springer (40)
  4. American Association for Cancer Research (36)
  5. Oxford University Press (29)
  6. C M P Medica LLC * The Oncology Group (14)

More Publishers

Results (318)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Treatment strategies for patients with anthracycline- and taxane-pretreated metastatic breast cancer
    Journal Article

    Seidman, A. D.
    Seminars in Oncology (2008)

    Fulltext@MSK | Save
  • Racial differences in clinical outcomes from metastatic breast cancer: A pooled analysis of CALGB 9342 and 9840 - Cancer and Leukemia Group B
    Journal Article

    Polite, B. N.; Cirrincione, C.; Fleming, G. F.; Berry, D. A.; Seidman, A.; Muss, H.; Norton, L.; Shapiro, C.; Bakri, K.; Marcom, K.; more...
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of Cancer and Leukemia Group B protocol 9840
    Journal Article

    Seidman, A. D.; Berry, D.; Cirrincione, C.; Harris, L.; Muss, H.; Marcom, P. K.; Gipson, G.; Burstein, H.; Lake, D.; Shapiro, C. L.; more...
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Metastatic breast cancer: How far we've come - The Higgins/Wolff article reviewed [Therapeutic options in the management of metastatic breast cancer]
    Journal Article

    Seidman, A. D.
    Oncology (Norwalk) (2008)

    Fulltext@MSK | Save
  • A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer
    Journal Article

    Dickler, M. N.; Rugo, H. S.; Eberle, C.; Brogi, E.; Caravelli, J.; Panageas, K. S.; Boyd, J.; Yeh, B.; Lake, D. E.; Dang, C.; more...
    Clinical Cancer Research (2008)

    Fulltext@MSK | Save
  • The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer
    Journal Article

    Dang, C.; Fornier, M.; Sugarman, S.; Troso-Sandoval, T.; Lake, D.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Dickler, M.; Currie, V.; more...
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: Current status and future opportunities
    Journal Article

    Conlin, A. K.; Seidman, A. D.
    Clinical Breast Cancer (2008)

    Fulltext@MSK | Save
  • CALGB 150002: Correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2+ and HER2- metastatic breast cancer (MBC)
    Meeting Abstract

    Kaufman, P. A.; Broadwater, G.; Lezon-Geyda, K.; Dressler, L. G.; Berry, D.; Friedman, P.; Winer, E. P.; Hudis, C.; Ellis, M. J.; Seidman, A. D.; more...
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Randomized phase II trial of three dosing schedules of nanoparticle albumin-bound paclitaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer: An initial interim safety report
    Meeting Abstract

    Conlin, A. K.; Seidman, A. D.; Moynahan, M. E.; Traina, T.; Mace, J. R.; Meiri, E.; Bach, A.; Edwards, C.; Hudis, C. A.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Oncotype DX: Therapeutic impact on decision-making
    Meeting Abstract

    Seidman, A.
    Cancer Investigation (2007)

    Fulltext@MSK | Save